Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 ...

Reduced risks seen for neurocognitive, coagulation, cardiometabolic disorders; increased risks seen for GI, arthritic disorders ...

A study analyzing data from over 2 million veterans found that GLP-1 receptor agonists, popular weight-loss drugs like ...

One in eight people living in the United States has taken a GLP-1 medication — such as Ozempic, Mounjaro, or Zepbound — for ...

A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

Health-care companies rose after more promising data for the best-selling Glucagon-like Peptide inhibitor drugs. Shares of Novo Nordisk and Eli Lilly, the two leading producers of GLP-1 drugs, rallied ...

While weight loss is a common new year's resolution for workers in the U.S., 2025 may mark the year that building weight loss ...

This is the beginning of a revolution, and how you engage and how you attack it is going to really set the stage for your ...

Websites that sell compounded glucagon-like peptide-1 receptor agonists (GLP-1 RAs) often partially inform or misinform ...